Q/C Technologies, Inc.
QCLS- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001321834
No open-market purchases or sales by Q/C Technologies, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $2.87M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Q/C Technologies, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 25 | 1 | 24 | 0 |
| Shares | 126.9K | 60 | 197.3K | +70.5K (+55.6%) |
| Value | $145.8K | $35 | $69.0K | −$76.8K (−52.7%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (3)
Institutions that held Q/C Technologies, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Change Path, LLC | 23,001 | $8.05K | 0.00% |
| Key Client Fiduciary Advisors, LLC | 20,000 | $7.00K | 0.00% |
| Jones Financial Companies LLLP | 201 | $72 | 0.00% |
Sold out (3)
Institutions that held Q/C Technologies, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Susquehanna International Group, LLP | 22,874 | $26.3K |
| Parallel Advisors, LLC | 838 | $964 |
| Dogwood Wealth Management LLC | 3 | $3 |
Not filed for Q1 2025 yet (1)
Institutions that held Q/C Technologies, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Legacy Investment Solutions, LLC | 60 | $35 |